# CRISPR Therapeutics

Type: Company (CRSP)

Source: GetYourBrief — https://getyourbrief.com/entity/crispr-therapeutics
Canonical HTML page: https://getyourbrief.com/entity/crispr-therapeutics

## Timeline

- **2026-03-11**: Offering Upsized — The company prices an upsized $550M offering due to strong institutional interest.
- **2026-03-11**: ARK Invest Trade — Cathie Wood's ARK Invest buys the dip, increasing its position in CRSP shares.
- **2026-03-10**: Debt Offering Announced — CRISPR Therapeutics announces a $350M convertible senior notes offering, causing a stock price dip.
- **2026-02-26**: Cure Announcement — Medical officials formally announce the patient is cured, marking a global first for gene editing technology.
- **2025-07-20**: Six-Month Follow-up — Clinical evaluations confirm significant biological markers of recovery and the absence of off-target effects.
- **2025-01-10**: Therapy Administration — A one-time gene editing intervention is administered at a specialized pediatric facility in British Columbia.
- **2024-06-15**: Trial Enrollment — The B.C. teen is enrolled in a world-first experimental gene editing clinical trial for a rare genetic disorder.

## Recent coverage (5 stories, network-wide)

### FDA Expands Gene Therapy to Kids 2+, Offering $2.2M Cure for Sickle Cell
2026-07-09 07:50:49 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 20

The FDA’s approval of Casgevy for children as young as two promises to shift pediatric sickle cell care from lifelong management to a one-time curative intervention, but raises urgent questions about cost, access, and health equity.
Full story: https://gethealthbrief.com/story/fda-approves-casgevy-pediatric-sickle-cell-health

### Casgevy Wins FDA Nod for Kids 2+, Widening $2.2M Gene Therapy Duel
2026-07-09 07:50:38 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 20

The FDA's expansion of Casgevy to children aged 2–11 solidifies Vertex and CRISPR Therapeutics' lead over bluebird bio’s Lyfgenia, opens a lucrative new patient segment, and validates the safety of CRISPR gene editing in very young patients.
Full story: https://getbiobrief.com/story/crispr-casgevy-pediatric-fda-approval-bio

### Cathie Wood Capitalizes on CRISPR Therapeutics Dip Amid $550M Debt Offering
2026-03-11 11:51:33 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ARK Invest founder Cathie Wood has increased her stake in CRISPR Therapeutics following a stock price decline triggered by a significant convertible debt offering. The move underscores Wood's long-term conviction in the gene-editing sector despite short-term market volatility and capital-raising pressures.
Full story: https://getfinancebrief.com/story/cathie-wood-buys-crispr-therapeutics-dip

### Cathie Wood’s ARK Invest Doubles Down on CRISPR Therapeutics Amid Market Dip
2026-03-11 11:48:57 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.
Full story: https://getbiobrief.com/story/cathie-wood-ark-invest-crispr-therapeutics-buy-dip

### B.C. Teen Becomes First in World Cured of Rare Disease via Gene Editing
2026-02-26 02:26:16 · Sector: bio · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

A British Columbia teenager has achieved a historic medical milestone, becoming the first person globally to be cured of a rare genetic disease using advanced gene editing technology. This breakthrough marks a definitive shift in the treatment of rare disorders, moving from chronic management to a potential one-time curative intervention.
Full story: https://getbiobrief.com/story/bc-teen-first-world-gene-editing-cure

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.